[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Steve E. Krognes, a director of Guardant Health, Inc. (GH), reported acquisitions on Form 4 dated 08/31/2025. The filing shows a non-derivative entry and a derivative entry reflecting restricted stock units. The non-derivative entry records 155 shares acquired on 08/31/2025 at an aggregate price of $0, bringing his direct beneficial ownership of common stock to 18,128 shares. The derivative section shows 155 restricted stock units reported on 08/31/2025 with a $0 price, corresponding to 1,543 shares of common stock beneficially owned following the transaction on a direct basis. Explanatory notes state the RSU award was granted on August 9, 2022, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the following three years.

Insights

Financial Analyst

TL;DR: Routine RSU vesting increases director's direct ownership by 155 units; no cash paid and no sale activity reported.

The Form 4 documents a non-cash acquisition of 155 restricted stock units reflected as both a non-derivative and derivative entry, consistent with standard equity compensation vesting. The disclosed figures—18,128 shares direct ownership and 1,543 derivative shares beneficially owned following the transaction—are purely ownership updates and do not indicate changes in company operations, liquidity, or capital structure. This filing should be interpreted as an insider compensation/ownership disclosure rather than an economic trade signal.

Corporate Governance Expert

TL;DR: Director reported RSU vesting per prior grant terms; disclosure aligns with Section 16 reporting requirements.

The explanatory note clarifies the RSU grant date (August 9, 2022) and vesting schedule (25% vested June 30, 2023; remainder vesting monthly over three years), which supports transparency about executive/director equity incentives. The filing was signed by an attorney-in-fact, consistent with authorized agent reporting practices. There are no indications of unusual related-party transactions or departures from standard governance disclosure norms in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2025		M		155	A	$0	18,128	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	08/31/2025		M			155	(1)	(2)	Common Stock	155	$0	1,543	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health director Steve Krognes report on Form 4 (GH)?

He reported the acquisition of 155 restricted stock units on 08/31/2025 at an aggregate price of $0.

How many Guardant Health (GH) shares does Steve Krognes beneficially own after this filing?

The filing shows 18,128 shares of common stock beneficially owned (direct) and 1,543 shares reflected from derivative holdings following the transaction.

When was the RSU grant that vested for Steve Krognes originally made?

The RSU award was granted on August 9, 2022, per the explanatory note in the filing.

What is the vesting schedule for the RSU award reported by Steve Krognes?

The award vested 25% on June 30, 2023, with the remaining 75% vesting in substantially equal monthly installments over the subsequent three-year period.

Was any cash paid for the RSUs reported on the Form 4 for GH?

No. The transaction price is listed as $0 in the filing.